1. Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesiumndelayed-release tablets in patients requiring chronic nonsteroidal anti-inﬂammatory drug therapy: an analysis from 5 Phase III studies
Dominick J. Angiolillo • Catherine Datto •Shane Raines • Neville D. Yeomans. J Thromb Thrombolysis (2014) 38:11–23
As a potential solution to the under-use of gastroprotective agents, a ﬁxed-dose combination of enteric-coated (EC) naproxen 500 mg and immediate-release (IR) esomeprazole magnesium 20 mg (naproxen/esomeprazole magnesium; NAP/ESO) has been designed to provide sequential delivery of, ﬁrst, a PPI, and then an NSAID from a single tablet. Phase III trials have demonstrated comparable efﬁcacy for NAP/ESO and celecoxib in the treatment of OA of the knee, while NAP/ESO was associated with a signiﬁcantly lower incidence of endoscopic Gus compared with EC naproxen in patients at risk for developing NSAID-associated ulcers . Furthermore, long-term (12-month) use of NAP/ESO was not associated with any new safety issues, including predeﬁned UGI and CV adverse events (AEs). The NAP/ESO combination is currently licensed in both the United States and Europe for the relief of signs and symptoms of OA, RA, and ankylosing spondylitis, and to decrease the risk for developing NSAID-associated GUs in at-risk patients.
2. The Role of Helicobacter pylori in Upper Respiratory System Infections: Is it More Than Colonization?
Mucahit Yemisen & Bilgul Mete & Asiye Kanbay &Ilker Inanc Balkan & Resat Ozaras. Curr Infect Dis Rep (2012) 14:128–136
In 2007, Talaat et al. studied HP status by serology in the patients with chronic cough, found high positive HP results in this group and concluded that HP may be a causative agent in the etiology of chronic laryngopharyngeal symptoms. Youssef et al. investigated LPR patients with laryngoscope, 24 hour pH monitoring and HP stool antigen (HPSA) detection. Then, they divided the HPSA positive patients in to two groups and gave one group only anti acid therapy (esomeprazole magnesium 40 mg) and HP eradication therapy (esomeprazole magnesium 40 mg, amoxicillin sodium 1 g, chlarithromycine 500 mg) to other group. They observed significantly higher improvement of LPR symptoms in the HP eradicated group (90% vs 40%) and reported that the eradication of HP must be considered in the patients with LPR symptoms and positive HP.
3. Preparation and characterization of pH-sensitive methyl methacrylate-g-starch/hydroxypropylated starch hydrogels: in vitro and in vivo study on release of esomeprazole magnesium
Pankaj Kumar & Ashok Laxmanrao Ganure & Bharat Bhushan Subudhi & Shubhanjali Shukla. Drug Deliv. and Transl. Res. (2015) 5:243–256
The model drug selected for the study is esomeprazole magnesium, a proton pump inhibitor which reduces acid secretion through inhibition of the H+/K+ ATPase in gastric parietal cells and used in treating gastroesophageal reflux disease (GERD). It is highly acid-labile and presents many formulation challenges. Therefore, this drug needs to be protected from the harsh environment in the stomach. In order to achieve this, pH-sensitive copolymeric hydrogel systems composed of starch/hydroxypropylated starch (Hpst) grafted with polymethyl methacrylate were prepared and loaded with esomeprazole magnesium.